Match!

Evaluation of cytoreductive surgery and HIPEC for peritoneal surface malignancies: analysis of 384 consecutive cases.

Published on Aug 1, 2019in Langenbeck's Archives of Surgery2.093
· DOI :10.1007/s00423-019-01805-x
Vignesh Narasimhan2
Estimated H-index: 2
(Peter MacCallum Cancer Centre),
Atandrila Das (Peter MacCallum Cancer Centre)+ 6 AuthorsAlexander G. Heriot40
Estimated H-index: 40
(Peter MacCallum Cancer Centre)
Abstract
Background Peritoneal surface malignancy (PSM) was historically associated with a poor survival. The adoption of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can now offer patients with PSM a favourable overall survival. Here, we report our single-institute outcomes following CRS and HIPEC for PSM and evaluate changes in our practice over time.
  • References (38)
  • Citations (0)
References38
Newest
#1Zachary E. Stiles (UTHSC: University of Tennessee Health Science Center)H-Index: 3
#2Andrew J. Murphy (UTHSC: University of Tennessee Health Science Center)H-Index: 3
Last. Jeremiah L. Deneve (UTHSC: University of Tennessee Health Science Center)H-Index: 11
view all 12 authors...
Background Desmoplastic small round cell tumor (DSRCT) is a rare intra-abdominal soft tissue sarcoma affecting adolescents and young adults. Cytoreduction, hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), and adjuvant radiotherapy may improve local control. We review our experience with patients who undergo CRS/HIPEC and adjuvant radiotherapy for DSRCT.
3 CitationsSource
#1T.S.K. Mok (CUHK: The Chinese University of Hong Kong)H-Index: 4
#2Yi-Long Wu (Academy of Medical Sciences, United Kingdom)H-Index: 62
Last. Alfred ZippeliusH-Index: 35
view all 249 authors...
Summary Background First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of 50% or greater. We investigated overall survival after treatment with pembrolizumab monotherapy in patients with a PD-L1 TPS of 1% or greater. Methods This randomised, open-label, phase 3 study was done in 213 medical centres in 32 countries. Eligible patien...
53 CitationsSource
#1Koen P. RoversH-Index: 5
#2Checca BakkersH-Index: 1
Last. I.H.J.T. de HinghH-Index: 36
view all 59 authors...
Background Upfront cytoreductive surgery with HIPEC (CRS-HIPEC) is the standard treatment for isolated resectable colorectal peritoneal metastases (PM) in the Netherlands. This study investigates whether addition of perioperative systemic therapy to CRS-HIPEC improves oncological outcomes.
2 CitationsSource
#1Nayef A. Alzahrani (UNSW: University of New South Wales)H-Index: 10
#2Sarah J. Valle (UNSW: University of New South Wales)H-Index: 7
Last. David L. Morris (UNSW: University of New South Wales)H-Index: 65
view all 26 authors...
4 CitationsSource
#1François QuenetH-Index: 25
#2Dominique EliasH-Index: 82
Last. Olivier GlehenH-Index: 46
view all 17 authors...
LBA3503Background: Promising results have been obtained during the last decade using cytoreductive surgery (CRS) plus HIPEC for selected patients with colorectal PC who are amenable to complete macroscopic resection. This is the first trial to evaluate the specific role of HIPEC, after CRS, for the treatment of PC of colorectal origin. Methods: Prodige 7 is a randomized phase III, multicenter trial. Patients with histologically proven and isolated PC, peritoneal cancer index (PCI) ≤25 were eligi...
66 CitationsSource
#1Willemien J. van Driel (NKI-AVL: Netherlands Cancer Institute)H-Index: 9
#2Simone N. Koole (NKI-AVL: Netherlands Cancer Institute)H-Index: 1
Last. Gabe S. Sonke (NKI-AVL: Netherlands Cancer Institute)H-Index: 28
view all 17 authors...
Abstract Background Treatment of newly diagnosed advanced-stage ovarian cancer typically involves cytoreductive surgery and systemic chemotherapy. We conducted a trial to investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery would improve outcomes among patients who were receiving neoadjuvant chemotherapy for stage III epithelial ovarian cancer. Methods In a multicenter, open-label, phase 3 trial, we randomly assigned 245 patients...
174 CitationsSource
#1Jon D. Vogel (Case Western Reserve University)H-Index: 23
#2Cagla Eskicioglu (Case Western Reserve University)H-Index: 6
Last. Scott R. SteeleH-Index: 22
view all 5 authors...
The American Society of Colon and Rectal Surgeons is dedicated to ensuring high-quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The Clinical Practice Guidelines Committee is composed of society members who are chosen
25 CitationsSource
#1Charlotte E. L. Klaver (UvA: University of Amsterdam)H-Index: 5
#2H. Groenen (UvA: University of Amsterdam)H-Index: 1
Last. Pieter J. Tanis (UvA: University of Amsterdam)H-Index: 22
view all 6 authors...
19 CitationsSource
#1Nayef A. Alzahrani (UNSW: University of New South Wales)H-Index: 10
#2Jorgen S. Ferguson (UNSW: University of New South Wales)H-Index: 2
Last. David L. Morris (UNSW: University of New South Wales)H-Index: 65
view all 6 authors...
Background Peritoneal carcinomatosis (PC) results from the secondary spread of many intraabdominal tumour types, such as colorectal malignancy (colorectal cancer, CRC), disseminated peritoneal adenomucinosis (DPAM), appendiceal cancer, ovarian carcinoma, sarcoma or from the occurrence of primary peritoneal disease such as peritoneal mesothelioma. The combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has seen improvements in survival in selected case...
13 CitationsSource
#1Eric Van Cutsem (Katholieke Universiteit Leuven)H-Index: 122
#2Andrés Cervantes (University of Valencia)H-Index: 56
Last. Dirk ArnoldH-Index: 8
view all 47 authors...
The clinical outcome for patients with metastatic CRC (mCRC) has improved greatly over the last 20 years. These ESMO consensus guidelines have been developed based on the current available evidence to provide a series of evidence-based recommendations to assist in the treatment and management of patients with mCRC in this rapidly evolving treatment setting.Colorectal cancer (CRC) is one of the most common malignancies in Western countries. Over the last 20 years, and the last decade in particula...
599 CitationsSource
Cited By0
Newest